A healthy investment in healthier futures.
Cryo-Cell has been a publicly traded company since 1991. Governed by the Securities & Exchange Commission, our common stock trades under the OTC QB: symbol CCEL. We specialize in stem cell preservation for family use.
Cryo-Cell Reports Fiscal Third Quarter 2018 Financial Results
Cryo-Cell International, Inc. (OTCQB:CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2018.
Arthur Ellis and Brian Sheehy Join Cryo-Cell’s Board of Directors
Cryo-Cell International announces that Arthur Ellis, JD, Board President of the Uptown People’s Law Center, and Brian Sheehy, M.D. M.A. C.F.A., Founder and Managing Partner IsZo Capital, have joined the company’s board of directors.
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2018 Financial Results
Cryo-Cell International, Inc. (OTCQB:CCEL), the world’s first private cord blood bank to separate and store stem cells, in 1992, announced results for the fiscal second quarter ended May 31, 2018.
Cryo-Cell Consummates Acquistion of Cord:Use Assets and Extends Its Leadership Position into the Public Cord Blood Banking Arena
Cryo-Cell International announced that it has completed its acquisition of substantially all of the assets of CORD:USE Cord Blood Bank, Inc. (“CORD:USE”) for an upfront purchase price of $14,000,000 plus up to $200 million in potential cash earnouts related to the CORD:USE public cord blood inventory and additional stock earnouts based upon Cryo-Cell achieving certain milestones associated with the purchased assets.
Cryo-Cell Acquires Cord:Use Cord Blood Bank
Cryo-Cell International, the world’s first private cord blood bank to separate and store stem cells in 1992, announced that it has entered into an agreement (the “Asset Purchase Agreement”) to acquire substantially all of the assets of Cord:Use Cord Blood Bank, Inc. (“CORD:USE”) for a purchase price of $14,000,000 with additional consideration subject to earnouts as set forth in the Asset Purchase Agreement. This acquisition will propel Cryo-Cell International into the public cord blood banking business and is expected to further solidify Cryo-Cell International’s role as the industry leader.